Suven Life Sciences Limited
SUVEN.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$64.75B
Close$
Share Statistics
| Market cap | $64.75 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.13 |
| Beta | 0.8 |
| Outstanding Shares | 282,562,686 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -19.49 |
|---|---|
| PEG | -13.19 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Suven Life Sciences Limited
138 employees
CEO: Venkateswarlu Jasti Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical firm dedicated to the acquisition, advancement, and global commercialization of innovative therapies. Operating across India, the United States, Europe, and other...